|
1）Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism. Nat Rev Cardiol. 2014; 11: 140-56
|
|
|
|
2）Yin T, Miyata T. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in northeast Asians. J Thromb Thrombolysis. 2014; 37: 56-65
|
|
|
|
|
|
3）Yamazaki T, Sugiura I, Matsushita T, et al. A phenotypically neutral dimorphism of protein S: the substitution of Lys155 by Glu in the second EGF domain predicted by an A to G base exchange in the gene. Thromb Res. 1993; 70: 395-403
|
|
|
|
|
|
4）Hayashi T, Nishioka J, Shigekiyo T, et al. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994; 83: 683-90
|
|
|
|
|
|
5）Miyata T, Hamasaki N, Wada H, et al. More on: racial differences in venous thromboembolism. J Thromb Haemost. 2012; 10: 319-20
|
|
|
|
|
|
6）Kinoshita S, Iida H, Inoue S, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem. 2005; 38: 908-15
|
|
|
|
|
|
7）Kimura R, Honda S, Kawasaki T, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006; 107: 1737-8
|
|
|
|
|
|
8）Ikejiri M, Wada H, Sakamoto Y, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol. 2010; 92: 302-5
|
|
|
|
|
9）Liu W, Yin T, Okuda H, et al. Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese. Thromb Res. 2013; 132: 314-5
|
|
|
|
|
|
10）Tang L, Jian XR, Hamasaki N, et al. Molecular basis of protein S deficiency in China. Am J Hematol. 2013; 88: 899-905
|
|
|
|
|
|
11）Miyata T, Sato Y, Ishikawa J, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009; 124: 14-8
|
|
|
|
|
|
12）Kimura R, Sakata T, Kokubo Y, et al. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost. 2006; 4: 2010-3
|
|
|
|
|
|
13）Neki R, Miyata T, Fujita T, et al. Nonsynonymous mutations in three anticoagulant genes in Japanese patients with adverse pregnancy outcomes. Thromb Res. 2014; 133: 914-8
|
|
|
|
|
|
14）Tsuda T, Jin X, Tsuda H, et al. New quantitative total protein S-assay system for diagnosing protein S type II deficiency: clinical application of the screening system for protein S type II deficiency. Blood Coagul Fibrinolysis. 2012; 23: 56-63
|
|
|
|
|
|
15）Maruyama K, Akiyama M, Kokame K, et al. ELISA-based detection system for protein S K196E mutation, a genetic risk factor for venous thromboembolism. PLoS One. 2015; 10: e0133196
|
|
|
|
|
|
16）Banno F, Kita T, Fernández JA, et al. Exacerbated venous thromboembolism in mice carrying protein S K196E mutation. Blood. 2015; 126: 2247-53
|
|
|
|
|
|
17）Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood. 2010; 116: 4353-9
|
|
|
|
|
|
18）Diaz JA, Alvarado CM, Wrobleski SK, et al. The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse. Thromb Haemost. 2013; 109: 1158-69
|
|
|
|
|
|
19）Tsay W, Shen MC. R147W mutation of PROC gene is common in venous thrombotic patients in Taiwanese Chinese. Am J Hematol. 2004; 76: 8-13
|
|
|
|
|
|
20）Tang L, Guo T, Yang R, et al. Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population. PLoS One. 2012; 7: e35773
|
|
|
|
|
|
21）Ding Q, Yang L, Hassanian SM, et al. Expression and functional characterisation of natural R147W and K150del variants of protein C in the Chinese population. Thromb Haemost. 2013; 109: 614-24
|
|
|
|
|
|
22）Tang L, Lu X, Yu JM, et al. PROC c. 574_576del polymorphism: a common genetic risk factor for venous thrombosis in the Chinese population. J Thromb Haemost. 2012; 10: 2019-26
|
|
|
|
|
|
23）http://www.genome.med.kyoto-u.ac.jp/SnpDB
|
|
|
|
|
|
24）Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012; 366: 2390-6
|
|
|
|
|
|
25）Djordjevic V, Kovac M, Miljic P, et al. A novel prothrombin mutation in two families with prominent thrombophilia--the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost. 2013; 11: 1936-9
|
|
|
|
|
|
26）Sivasundar S, Oommen AT, Prakash O, et al. Molecular defect of ʼProthrombin Amritaʼ: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis. 2013; 50: 182-3
|
|
|
|
|
|
27）Murata M, Takagi A, Suzuki A, et al. Development of a new laboratory test to evaluate antithrombin resistance in plasma. Thromb Res. 2014; 133: 293-8
|
|
|
|
|
|
28）ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014; 12: 1580-90
|
|
|
|
|
|
29）Miyata T, Sakata T, Yasumuro Y, et al. Genetic analysis of protein C deficiency in nineteen Japanese families: five recurrent defects can explain half of the deficiencies. Thromb Res. 1998; 92: 181-7
|
|
|
|
|
|
30）Kerlin BA, Yan SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003; 102: 3085-92
|
|
|
|
|
|
31）Wang H, Madhusudhan T, He T, et al. Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood. 2011; 117: 5231-42
|
|
|
|
|
|
32）The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature. 2010; 467: 1061-73
|
|
|
|
|